Asparaginase Global Market Report 2022: Increase in R&D Activities and Investment by Market Players Presents Opportunities
13 oct. 2022 07h33 HE
|
Research and Markets
Dublin, Oct. 13, 2022 (GLOBE NEWSWIRE) -- The "Asparaginase Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Application, End-Use Industry, and Geography" report has been added...
Global Leukemia Drug Market Report 2020-2025: Comprehensive Clinical Trials Insights of 633 Drugs
10 sept. 2020 08h48 HE
|
Research and Markets
Dublin, Sept. 10, 2020 (GLOBE NEWSWIRE) -- The "Global Leukemia Drug Market, Drug Price, Patent, Dosage & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's...
ERYTECH annonce le recrutement des premiers patients dans son étude clinique de Phase 3 avec eryaspase pour le traitement en seconde ligne du cancer du pancréas
20 sept. 2018 01h30 HE
|
Erytech Pharma S.A.
LYON, France et CAMBRIDGE, Mass., 20 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), société biopharmaceutique de stade clinique qui développe des thérapies...
ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer
20 sept. 2018 01h30 HE
|
Erytech Pharma S.A.
LYON, France and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies...
ERYTECH publie ses résultats financiers et fait le point sur ses activités du premier semestre 2018
10 sept. 2018 16h30 HE
|
Erytech Pharma S.A.
Conférence téléphonique et webcast : mardi 11 septembre à 14h30 Confirmation du virage stratégique entrepris vers le développement d’eryaspase dans les tumeurs solidesLancement de l’étude de Phase...
ERYTECH Reports First Half of 2018 Financial Results and Provides Business Update
10 sept. 2018 16h30 HE
|
Erytech Pharma S.A.
Conference call and webcast scheduled for Tuesday, September 11that 2:30 pm CET/8:30 am EDT Strategic shift to development of eryaspase for solid tumors confirmedPhase 3 trial for eryaspase in second...
ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018
15 juin 2018 01h30 HE
|
Erytech Pharma S.A.
LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic...
ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update
14 mai 2018 16h30 HE
|
Erytech Pharma S.A.
Finalized Phase 3 trial design for eryaspase in second line pancreatic cancer; on track for expected start of patient enrollment in Q3Selected triple-negative breast cancer as the next solid tumor...
ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy
14 mai 2018 01h30 HE
|
Erytech Pharma S.A.
LYON, France, May 14, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic...
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F
24 avr. 2018 16h30 HE
|
Erytech Pharma S.A.
LYON, France, April 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of...